Weed, Inc. (BUDZ): EBITDA
-$1.31M
Year ended 2025-12-31
-$1.03M
Trailing 12 months to 2026-06-30
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$1.31M | n/m | 2026-04-08, From 2025-01-01 |
| 2024-12-31 | -$507.4K | n/m | 2026-04-08, From 2024-01-01 |
| 2023-12-31 | -$718.2K | n/m | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | -$1.39M | n/m | 2024-04-01, From 2022-01-01 |
| 2021-12-31 | -$2.67M | n/m | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | -$3.93M | n/m | 2022-03-31, From 2020-01-01 |
| 2019-12-31 | -$27.26M | n/m | 2021-03-31, From 2019-01-01 |
| 2018-12-31 | -$28.22M | n/c | 2020-03-30, From 2018-01-01 |
| 2017-12-31 | -$2.34M | n/a | 2019-04-16, From 2017-01-01 |
| No annual figure between 2011-12-31 and 2017-12-31. | |||
| 2011-12-31 | $2.09M | +321.1% | 2012-04-16, From 2011-01-01 |
| 2010-12-31 | $495.9K | n/a | 2012-04-16, From 2010-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Weed, Inc. (BUDZ) | 2025-12-31 | -$1.31M | n/m |
| NRC Health (NRC) | 2025-12-31 | $30.21M | -26.7% |
| Incyte Corp (INCY) | 2025-12-31 | $1.61B | +967.7% |
| Icon PLC (ICLR) | 2025-12-31 | $825.84M | -45.7% |
| Charles River Laboratories International, Inc. (CRL) | 2025-12-27 | $428.47M | -27.3% |
| MaxCyte, Inc. (MXCT) | 2025-12-31 | -$47.56M | n/m |
| Iqvia Holdings Inc. (IQV) | 2025-12-31 | $3.33B | +0.3% |
| iSpecimen Inc. (ISPC) | 2025-12-31 | -$7.25M | n/m |
| Absci Corp (ABSI) | 2025-12-31 | -$108.58M | n/m |
Compare BUDZ, NRC, INCY, ICLR side by side · Screen every company in Services-Commercial Physical & Biological Research ↗